236 related articles for article (PubMed ID: 36628520)
1. Oral immunotherapy using boiled peanuts for treating peanut allergy: An open-label, single-arm trial.
Grzeskowiak LE; Tao B; Aliakbari K; Chegeni N; Morris S; Chataway T
Clin Exp Allergy; 2023 Mar; 53(3):327-336. PubMed ID: 36628520
[TBL] [Abstract][Full Text] [Related]
2. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
3. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy.
Reier-Nilsen T; Michelsen MM; Lødrup Carlsen KC; Carlsen KH; Mowinckel P; Nygaard UC; Namork E; Borres MP; Håland G
Allergy; 2019 Feb; 74(2):337-348. PubMed ID: 30225844
[TBL] [Abstract][Full Text] [Related]
5. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial: a critical appraisal.
Marrs T; Flohr C; Perkin MR
Br J Dermatol; 2015 Nov; 173(5):1125-9. PubMed ID: 26769642
[TBL] [Abstract][Full Text] [Related]
6. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
Anagnostou K; Islam S; King Y; Foley L; Pasea L; Bond S; Palmer C; Deighton J; Ewan P; Clark A
Lancet; 2014 Apr; 383(9925):1297-1304. PubMed ID: 24485709
[TBL] [Abstract][Full Text] [Related]
7. Peanut oral immunotherapy using an extensively heated and baked novel composition of peanuts.
Kidon MI; Shavit R; Levy Y; Haj Yahia S; Machnes-Maayan D; Frizinsky S; Maoz-Segal R; Offenganden I; Kenett RS; Nancy AL; Hovav R
Pediatr Allergy Immunol; 2024 May; 35(5):e14146. PubMed ID: 38783409
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.
Schneider LC; Rachid R; LeBovidge J; Blood E; Mittal M; Umetsu DT
J Allergy Clin Immunol; 2013 Dec; 132(6):1368-74. PubMed ID: 24176117
[TBL] [Abstract][Full Text] [Related]
10. Extended boiling of peanut progressively reduces IgE allergenicity while retaining T cell reactivity.
Tao B; Bernardo K; Eldi P; Chegeni N; Wiese M; Colella A; Kral A; Hayball J; Smith W; Forsyth K; Chataway T
Clin Exp Allergy; 2016 Jul; 46(7):1004-14. PubMed ID: 27079163
[TBL] [Abstract][Full Text] [Related]
11. Early Peanut Immunotherapy in Children (EPIC) trial: protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age.
O'Sullivan MD; Bear N; Metcalfe J
BMJ Paediatr Open; 2023 Nov; 7(1):. PubMed ID: 37963680
[TBL] [Abstract][Full Text] [Related]
12. High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small Children Oral Immunotherapy (SmaChO) Randomized Controlled Trial.
Uhl C; Klevebro S; Sverremark-Ekström E; Tedner SG; Brandström J; Papageorgiou C; Melén E; Konradsen JR; Nilsson C; Asarnoj A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1297-1305. PubMed ID: 38428524
[TBL] [Abstract][Full Text] [Related]
13. The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial.
Yu GP; Weldon B; Neale-May S; Nadeau KC
Int Arch Allergy Immunol; 2012; 159(2):179-82. PubMed ID: 22678151
[TBL] [Abstract][Full Text] [Related]
14. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.
Varshney P; Jones SM; Scurlock AM; Perry TT; Kemper A; Steele P; Hiegel A; Kamilaris J; Carlisle S; Yue X; Kulis M; Pons L; Vickery B; Burks AW
J Allergy Clin Immunol; 2011 Mar; 127(3):654-60. PubMed ID: 21377034
[TBL] [Abstract][Full Text] [Related]
16. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
Nagakura KI; Yanagida N; Sato S; Nishino M; Asaumi T; Ogura K; Ebisawa M
Pediatr Allergy Immunol; 2018 Aug; 29(5):512-518. PubMed ID: 29603410
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome.
Anagnostou K; Clark A; King Y; Islam S; Deighton J; Ewan P
Clin Exp Allergy; 2011 Sep; 41(9):1273-81. PubMed ID: 21414048
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
[TBL] [Abstract][Full Text] [Related]
19. First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy.
Soller L; Abrams EM; Carr S; Kapur S; Rex GA; Leo S; Lidman PG; Yeung J; Vander Leek TK; McHenry M; Wong T; Cook VE; Hildebrand KJ; Gerstner TV; Mak R; Lee NJ; Cameron SB; Chan ES
J Allergy Clin Immunol Pract; 2019; 7(8):2759-2767.e5. PubMed ID: 31002957
[TBL] [Abstract][Full Text] [Related]
20. Peanut Oral Immunotherapy With or Without H
Chu DK; Freitag T; Marrin A; Walker TD; Avilla E; Freitag A; Spill P; Foster GA; Thabane L; Jordana M; Waserman S
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2386-2394. PubMed ID: 35643280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
